SELLAS Life Sciences Group, Inc. R&D Expense

Quick Answer

SELLAS Life Sciences Group, Inc. reported R&D Expense of $15.67 million for fiscal year 2021.

SELLAS Life Sciences Group, Inc. R&D Expense — Annual History

Fiscal Year R&D Expense YoY Change
2021 $15.67M +68.9%
2020 $9.28M +27.4%
2019 $7.29M -16.9%
2018 $8.77M +44.5%
2017 $6.07M -46.8%
2016 $11.39M -22.0%
2012 $14.61M +279.5%
2011 $3.85M -51.1%
2010 $7.87M

Quarterly R&D Expense

Quarter Ending R&D Expense YoY QoQ
September 30, 2021 $4.54M +91.8% +31.4%
June 30, 2021 $3.46M +51.6% -19.3%
March 31, 2021 $4.28M +129.8% +81.0%
September 30, 2020 $2.37M +31.6% +3.8%
June 30, 2020 $2.28M +65.1% +22.3%
March 31, 2020 $1.86M +0.3% +3.6%
September 30, 2019 $1.80M +4.6% +30.3%
June 30, 2019 $1.38M -13.3% -25.7%
  • SELLAS Life Sciences Group, Inc. showed an increase of +68.9% in R&D Expense compared to the prior fiscal year.
  • Over the 2010–2021 period, SELLAS Life Sciences Group, Inc.’s r&d expense has grown by 99.1% (from $7.87 million to $15.67 million).
  • The most recent figure is from SELLAS Life Sciences Group, Inc.’s fiscal year 2021 report (Form 10-K), filed with the SEC on March 31, 2022.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment